The present invention provides a compound represented by formula (I), or a pharmaceutically acceptable salt or prodrug thereof. ##STR00001##

Disclosed herein are hydroxamic acid compounds. Also disclosed is a method of using the hydroxamic acid compounds for treating a condition associated with histone deacetylase 6.

Disclosed herein are hydroxamic acid compounds. Also disclosed is a method of using the hydroxamic acid compounds for treating a condition associated with histone deacetylase 6.

The present invention relates to the technical field of chemical synthesis of pharmaceutical chemicals, and provides a 6H-imidazo[4,5,1-ij]quinolone, a synthesis method and use thereof. 6H-imidazo[4,5,1-ij]quinolone derivatives provided by the present invention are a novel group of active quinolone derivatives, which have tumor cell inhibition activity and exhibit IC.sub.50 values equivalent to anti-lung cancer drug osimertinib; these quinolone derivatives have a broad application prospect in the preparation of antitumor drugs. The 6H-imidazo[4,5,1-ij]quinolone provided by the present invention is of high research and application value and has potential application prospects in fields of pharmaceutical chemicals, materials, dyes, etc. The present invention uses thioquinolinamide as a raw material to synthesize 6H-imidazo[4,5,1-ij]quinolones, featuring simple operation, excellent selectivity, high yield, mild reaction conditions, and easy product separation.

The present invention relates to the technical field of chemical synthesis of pharmaceutical chemicals, and provides a 6H-imidazo[4,5,1-ij]quinolone, a synthesis method and use thereof. 6H-imidazo[4,5,1-ij]quinolone derivatives provided by the present invention are a novel group of active quinolone derivatives, which have tumor cell inhibition activity and exhibit IC.sub.50 values equivalent to anti-lung cancer drug osimertinib; these quinolone derivatives have a broad application prospect in the preparation of antitumor drugs. The 6H-imidazo[4,5,1-ij]quinolone provided by the present invention is of high research and application value and has potential application prospects in fields of pharmaceutical chemicals, materials, dyes, etc. The present invention uses thioquinolinamide as a raw material to synthesize 6H-imidazo[4,5,1-ij]quinolones, featuring simple operation, excellent selectivity, high yield, mild reaction conditions, and easy product separation.

Sensors for detecting and distinguishing metals in a sample comprise phenol group-containing azo dyes, the phenol group having one hydroxy involved in reversible metal ion binding and a second hydroxy alkylated to an optically transparent substrate. The sensors have utility for detecting chromium, calcium, magnesium, copper, mercury, nickel, zinc, cobalt, manganese, cadmium, lead, tin, aluminum, potassium, sodium, or arsenic ions in a sample.

Provided herein are compounds for use as photochromic molecular switches having very long thermal isomerization half-lives and switchable fluorescence properties both in solution and the solid state.

Provided herein are compounds for use as photochromic molecular switches having very long thermal isomerization half-lives and switchable fluorescence properties both in solution and the solid state.

This invention is in the field of medicinal chemistry. In particular, the invention relates to anew class of small-molecules having a quinolinyl-pyrazine-carboxamide (or similar) structure which function as activators of the cholesterol biosynthesis pathway within cancer cells and/or immune cells, which function as activators of the cell cycle regulation pathway within cancer cells and/or immune cells, and which function as up-regulators of HMGCS1 protein expression within cancer cells and/or immune cells, and which function as effective therapeutic agents for treating, ameliorating, and preventing various forms of cancer and other inflammatory disease.

The present invention relates to compounds that have zinc and/or iron ionophore activity and their use in treating diseases that are modulated by reducing zinc and/or iron. In particular embodiments, the compounds are compounds of formula (I):

##STR00001##